Thirty-six buys, one maintain and no sells: Medical device maker Boston Scientific is in fairly rarified air so far as Wall Street’s sell-side analysts are involved. Why is that? Much of the funding world’s focus has rightly been directed at the AI build-out. It is, in spite of everything, a compelling development story. However, there are different corporations that have been rising quickly, and for these searching for alternatives exterior the AI sector, Boston Scientific (NYSE: BSX) could also be price contemplating. The firm’s sturdy presence in cardiology, endoscopy, and neuromodulation has contributed to spectacular high and bottom-line development. The second quarter this yr continued the regular five-year pattern of gross sales development, with web gross sales reaching $5.06 billion, representing a 22.8% year-over-year enhance. Adjusted earnings per share (EPS) of 75 cents exceeded analyst expectations by 2.74%. This was largely due to a 29% surge in cardiovascular revenues from merchandise like the WATCHMAN left atrial appendage closure device and the FARAPULSE pulsed subject ablation system. Consequently, Boston Scientific raised its full-year 2025 steerage, now projecting 14%-15% natural gross sales development and adjusted EPS of $2.95 to $2.99 (Street consensus is 2.98), and the common of analysts’ estimates for FY 2026 is 3.41/share, which might characterize 14.3% YoY adjusted EPS development. As of Friday’s $97.32 closing worth, BSX is buying and selling solely a flip or so increased than the S & P whereas rising at double the tempo. Strategic acquisitions are additional enhancing this development trajectory. The $88 million deal for Elutia’s BioEnvelope enterprise, efficient on Oct. 1, is predicted to improve safety for implantable gadgets. Earlier integrations of SoniVie’s TIVUS Intravascular Ultrasound System and Bolt Medical’s coronary lithotripsy expertise have expanded capabilities in renal denervation and vascular intervention. With the pending acquisition of Cortex, anticipated in the first half of 2025, BSX can be set to advance neurovascular therapies. The firm experiences earnings on Oct. 22 (Street estimates are for about 71 cents per share); nevertheless, this shouldn’t be a stock that traditionally strikes considerably on earnings. The one-day common earnings-related transfer is lower than 3%, though options premia are barely elevated. Arguably, the greatest knock on the stock is technical. While the market is buying and selling at all-time highs, BSX has fallen nearly 10% since early September. Most technical indicators stay bullish, however not all. Consequently, a modestly bullish strategy could characterize a barely extra conservative bullish play than shopping for the stock (or upside calls) outright. As a stock substitute, one would possibly think about the following calendar name unfold threat reversal. Selling a nearer-dated strangle in opposition to a longer-dated name buy with a modest preliminary outlay. DISCLOSURES: All opinions expressed by the CNBC Pro contributors are solely their opinions and don’t mirror the opinions of CNBC, NBC UNIVERSAL, their guardian firm or associates, and should have been beforehand disseminated by them on tv, radio, web or one other medium. THE ABOVE CONTENT IS SUBJECT TO OUR TERMS AND CONDITIONS AND PRIVACY POLICY . THIS CONTENT IS PROVIDED FOR INFORMATIONAL PURPOSES ONLY AND DOES NOT CONSITUTE FINANCIAL, INVESTMENT, TAX OR LEGAL ADVICE OR A RECOMMENDATION TO BUY ANY SECURITY OR OTHER FINANCIAL ASSET. THE CONTENT IS GENERAL IN NATURE AND DOES NOT REFLECT ANY INDIVIDUAL’S UNIQUE PERSONAL CIRCUMSTANCES. THE ABOVE CONTENT MIGHT NOT BE SUITABLE FOR YOUR PARTICULAR CIRCUMSTANCES. BEFORE MAKING ANY FINANCIAL DECISIONS, YOU SHOULD STRONGLY CONSIDER SEEKING ADVICE FROM YOUR OWN FINANCIAL OR INVESTMENT ADVISOR. Click right here for the full disclaimer.